A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to define the safety profile of rituximab given intrathecally in
lymphomatous meningitis related to CD20+ non-Hodgkin's lymphomas.
Phase:
Phase 1
Details
Lead Sponsor:
International Extranodal Lymphoma Study Group (IELSG)